AR010102A1 - VACUNA VIVA RECOMBINANTE AVIARIA QUE COMPRENDE CoMO VECTOR UN VIRUS ILTV QUE COMPRENDE Y EXPRESA AL MENOS UNA SECUENCIA NUCLEOTíDICAHETERoLOGA - Google Patents
VACUNA VIVA RECOMBINANTE AVIARIA QUE COMPRENDE CoMO VECTOR UN VIRUS ILTV QUE COMPRENDE Y EXPRESA AL MENOS UNA SECUENCIA NUCLEOTíDICAHETERoLOGAInfo
- Publication number
- AR010102A1 AR010102A1 ARP980100145A ARP980100145A AR010102A1 AR 010102 A1 AR010102 A1 AR 010102A1 AR P980100145 A ARP980100145 A AR P980100145A AR P980100145 A ARP980100145 A AR P980100145A AR 010102 A1 AR010102 A1 AR 010102A1
- Authority
- AR
- Argentina
- Prior art keywords
- iltv
- understands
- requested
- expresses
- vector
- Prior art date
Links
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 title abstract 5
- 108010008038 Synthetic Vaccines Proteins 0.000 title 1
- 229940124551 recombinant vaccine Drugs 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 241000287828 Gallus gallus Species 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000271566 Aves Species 0.000 abstract 1
- 208000006758 Marek Disease Diseases 0.000 abstract 1
- 208000010359 Newcastle Disease Diseases 0.000 abstract 1
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 229940031348 multivalent vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La vacuna viva recombinante aviaria comprende como vector un virus ILTV queexpresa al menos una secuencia nucleotídica heterologa, estando insertada esta snucleotídica en el sitio de insercion formado por el intergen situado entre los los cuadros abiertos de lectura D y E del ILTV y que, en una cepa de ILTV particdefinido entre los nucleotidos 3873 y 4260 en SEQ ID NO:1. La secuencia nucleotíestar bajo el control de un promotor eucatiotido fuerte, tal como el promotor CMprovenir de los virus dela enfermedad de Newcastle, de la enfermedad de Marek, enfermedad de Gumboro, de la bronquitis infecciosa, de la anemia del pollo, de lneumovirosis del pollo. También se propone una formula de vacuna multivalente qucomprende al menos dos vacunas vivas segun la invencion, y el virus ILTV así recDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTEDATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE DATOS DEL DISQUETTE PRESENTADO POR EL SOLICITANTE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9701317A FR2758986B1 (fr) | 1997-01-31 | 1997-01-31 | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR010102A1 true AR010102A1 (es) | 2000-05-17 |
Family
ID=9503369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980100145A AR010102A1 (es) | 1997-01-31 | 1998-01-13 | VACUNA VIVA RECOMBINANTE AVIARIA QUE COMPRENDE CoMO VECTOR UN VIRUS ILTV QUE COMPRENDE Y EXPRESA AL MENOS UNA SECUENCIA NUCLEOTíDICAHETERoLOGA |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6306400B1 (es) |
| EP (1) | EP0968297B1 (es) |
| JP (1) | JP2001511142A (es) |
| AR (1) | AR010102A1 (es) |
| AU (1) | AU735265B2 (es) |
| CO (1) | CO4650230A1 (es) |
| FR (1) | FR2758986B1 (es) |
| MA (1) | MA24458A1 (es) |
| TN (1) | TNSN98015A1 (es) |
| WO (1) | WO1998033928A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632664B1 (en) | 1997-10-03 | 2003-10-14 | Nippon Zeon Co., Ltd. | Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same |
| AR031405A1 (es) * | 2000-11-21 | 2003-09-24 | Wyeth Corp | Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo |
| EP1241177A1 (en) * | 2001-03-15 | 2002-09-18 | Akzo Nobel N.V. | Recombinant infectious laryngotracheitis virus vaccine |
| EP2390352A1 (en) | 2003-03-18 | 2011-11-30 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| WO2005027829A2 (en) * | 2003-09-03 | 2005-03-31 | Intralytix, Inc. | Method for vaccination of poultry by bacteriophage lysate |
| US20050214316A1 (en) | 2003-11-13 | 2005-09-29 | Brown Thomas P | Methods of characterizing infectious bursal disease virus |
| US20050202484A1 (en) | 2004-02-19 | 2005-09-15 | The Governors Of The University Of Alberta | Leptin promoter polymorphisms and uses thereof |
| HRP20100314T1 (hr) | 2005-04-25 | 2010-08-31 | Merial Ltd. | Cjepivo protiv nipah virusa |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| JP2009515529A (ja) | 2005-11-14 | 2009-04-16 | メリアル リミテッド | 腎不全のための遺伝子療法 |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| US7794714B2 (en) * | 2008-03-14 | 2010-09-14 | The United States Of America As Represented By The Secretary Of Agriculture | Newcastle disease virus monoclonal antibodies |
| MX2011010406A (es) | 2009-04-03 | 2012-01-20 | Merial Ltd | Vacunas aviares vectorizadas con el virus de la emfermedad de newcastle. |
| WO2011090708A2 (en) | 2009-12-28 | 2011-07-28 | Merial Limited | Recombinant ndv antigen and uses thereof |
| EP3156070A3 (en) | 2010-08-31 | 2017-06-14 | Merial Inc. | Newcastle disease virus vectored herpesvirus vaccines |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| AU2012240240A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| WO2012138789A2 (en) | 2011-04-04 | 2012-10-11 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| WO2012145577A1 (en) | 2011-04-20 | 2012-10-26 | Merial Limited | Adjuvanted rabies vaccine with improved viscosity profile |
| EP2701736A1 (en) | 2011-04-25 | 2014-03-05 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
| CA2837375C (en) | 2011-06-01 | 2019-07-16 | Merial Limited | Needle-free administration of prrsv vaccines |
| HUE035774T2 (en) | 2011-08-12 | 2018-05-28 | Merial Inc | Biological substances, in particular vaccines, preserved by vacuum |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| WO2014164697A1 (en) | 2013-03-12 | 2014-10-09 | Merial Limited | Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof |
| CN104164408B (zh) * | 2013-05-15 | 2016-12-28 | 普莱柯生物工程股份有限公司 | 抗鸡新城疫、传染性支气管炎和禽流感疫苗组合物及制备 |
| US10010499B2 (en) | 2014-11-03 | 2018-07-03 | Merial Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| CA2990643C (en) | 2015-06-23 | 2023-10-17 | Merial, Inc. | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof |
| KR102780119B1 (ko) | 2016-12-14 | 2025-03-12 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 조류 병원체의 다중 항원을 발현하는 재조합 hvt 벡터 및 그를 포함하는 백신 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992003554A1 (en) * | 1990-08-24 | 1992-03-05 | Arthur Webster Pty. Ltd. | Infectious laryngotracheitis virus vaccine |
| WO1996000791A1 (en) * | 1994-06-30 | 1996-01-11 | The Board Of Trustees Of The University Of Illinois | Recombinant infectious laryngotracheitis virus and vaccine |
| FR2728795B1 (fr) * | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire |
-
1997
- 1997-01-31 FR FR9701317A patent/FR2758986B1/fr not_active Expired - Lifetime
-
1998
- 1998-01-13 AR ARP980100145A patent/AR010102A1/es unknown
- 1998-01-19 CO CO98001954A patent/CO4650230A1/es unknown
- 1998-01-23 MA MA24942A patent/MA24458A1/fr unknown
- 1998-01-23 AU AU62177/98A patent/AU735265B2/en not_active Expired
- 1998-01-23 WO PCT/FR1998/000122 patent/WO1998033928A1/fr not_active Ceased
- 1998-01-23 JP JP53258198A patent/JP2001511142A/ja active Pending
- 1998-01-23 EP EP98904207A patent/EP0968297B1/fr not_active Expired - Lifetime
- 1998-01-27 TN TNTNSN98015A patent/TNSN98015A1/fr unknown
-
1999
- 1999-07-28 US US09/362,831 patent/US6306400B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU735265B2 (en) | 2001-07-05 |
| FR2758986B1 (fr) | 1999-04-30 |
| WO1998033928A1 (fr) | 1998-08-06 |
| EP0968297B1 (fr) | 2005-03-23 |
| AU6217798A (en) | 1998-08-25 |
| US6306400B1 (en) | 2001-10-23 |
| CO4650230A1 (es) | 1998-09-03 |
| JP2001511142A (ja) | 2001-08-07 |
| TNSN98015A1 (fr) | 2005-03-15 |
| MA24458A1 (fr) | 1998-10-01 |
| EP0968297A1 (fr) | 2000-01-05 |
| FR2758986A1 (fr) | 1998-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR010102A1 (es) | VACUNA VIVA RECOMBINANTE AVIARIA QUE COMPRENDE CoMO VECTOR UN VIRUS ILTV QUE COMPRENDE Y EXPRESA AL MENOS UNA SECUENCIA NUCLEOTíDICAHETERoLOGA | |
| US12440555B2 (en) | Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species | |
| AR008620A1 (es) | Vacuna viva recombinante, fragmento de adn y virus iltv que la componen | |
| HUP9902790A2 (hu) | Madarakban alkalmazható polinukleotid-vakcinakészítmények | |
| EP1298139A3 (en) | Avian herpes virus-based recombinant infectious bursal disease vaccine | |
| CO4650231A1 (es) | Vacuna viva recombinante aviaria que utiliza como vector el virus de laringotraqueitis infecciosa aviaria | |
| JP2018519826A (ja) | アヒル腸炎ウイルス及びその使用 | |
| US10758608B2 (en) | Vaccine in the form of a recombinant sero type 9 avian adenovirus vector | |
| CA2110505A1 (en) | Infectious bursal disease virus recombinant poxvirus vaccine | |
| AR037062A1 (es) | Vacuna adn adyuvada y utilizacion de un compuesto elegido entre los polimeros del acido acrilico o metacrilico y los copolimeros de anhidrido maleico y de derivado alquenilo para adyuvar a dicha vacuna adn | |
| CA2417923A1 (en) | Vaccination against host cell-associated herpesviruses | |
| EP0690912A1 (en) | Recombinant avian adenovirus vector | |
| Cook et al. | Use of an infectious bronchitis virus and Escherichia coli model infection to assess the ability to vaccinate successfully against infectious bronchitis in the presence of maternally‐derived immunity | |
| Dhinakar Raj et al. | Genomic characterization of Indian isolates of egg drop syndrome 1976 virus | |
| Tomley | Recombinant vaccines for poultry | |
| US5874303A (en) | Sustainable cell line for the production of Marek's disease vaccines | |
| ECSP972164A (es) | Vacunas de uso aviario a base de virus de laringotraqueitis infecciosa | |
| RU94042470A (ru) | Поливалентная вакцина для профилактики болезни марека и способ ее изготовления | |
| CO2026000061A2 (es) | Gallid alphaherpesvirus 3 (mdv-2), un vector viral contra diferentes patógenos aviares: una nueva estrategia de vacunación en la industria avícola | |
| AU676042B2 (en) | Recombinant avian adenovirus vector | |
| AR031405A1 (es) | Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo | |
| TH31920B (th) | รีคอมบิแนนท์วัคซีนของนกชนิดที่มีชีวิตโดยใช้เฮอร์ปีส์ไวรัสของนกเป็นเวกเตอร์ |